Impact of high-pressure/high-dose pressurized intraperitoneal aerosol chemotherapy (HP/HD PIPAC) on perioperative outcome and overall survival in patients with advanced peritoneal carcinomatosis

Impact of high-pressure/high-dose pressurized intraperitoneal aerosol chemotherapy (HP/HD PIPAC) on perioperative outcome and overall survival in patients with advanced peritoneal carcinomatosis - PIPAC DruDo 2023

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032990

Enrollment

152

Registered

2023-11-07

Start date

2023-11-20

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C78.6 C18 C19 C20

Interventions

Group 1: All patients who received HP/HD PIPAC between 04/2018 and 08/2023 at Klinikum Dortmund for peritoneal carcinomatosis with colorectal cancer. Perioperative treatment data such as laboratory re

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who underwent surgery for PIPAC because of peritoneal carcinomatosis

Exclusion criteria

Exclusion criteria: Patients who objected to retrospective data analysis

Design outcomes

Primary

Measure	Time frame
The primary endpoint is mortality after PIPAC therapy. This is determined by a one-time query from relatives, other medical practitioners or the residents' registration office.	—

Secondary

Measure	Time frame
Perioperative outcome with complications and morbidity is recorded retrospectively once based on the treatment files.	—

Countries

Germany

Contacts

Public ContactUrs Giger-Pabst

Fliedner Fachhochschule Düsseldorf

ursgiger@gmx.net+49 211 409 3232

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026